FDA approves cancer drug belantamab mafodotin-blmf for relapsed multiple myeloma in combination with bortezomib and dexamethasone.

GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings ...

A recent study shows adults with cardiovascular disease (CVD) have a higher risk of developing shingles. People who have two ...

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has announced the purchase of 248,000 of its own ordinary shares as part ...

The U.S. Supreme Court declined on Monday to hear a bid by a group of physicians and healthcare providers to revive their ...

The Catawba County Public Health Community Health Workers program is dedicated to ensuring that all families in Catawba ...

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive ...

GlaxoSmithKline ( ($GB:GSK) ) has issued an update. GSK plc announced the purchase of 340,000 of its own ordinary shares as part of its ongoing ...

Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher valuation multiples. Learn more about GSK stock here.